| Literature DB >> 17655039 |
Gary J Kelloff1, Daniel C Sullivan, Houston Baker, Lawrence P Clarke, Robert Nordstrom, James L Tatum, Gary S Dorfman, Paula Jacobs, Christine D Berg, Martin G Pomper, Michael J Birrer, Margaret Tempero, Howard R Higley, Brenda Gumbs Petty, Caroline C Sigman, Carlo Maley, Prateek Sharma, Adam Wax, Gregory G Ginsberg, Andrew J Dannenberg, Ernest T Hawk, Edward M Messing, H Barton Grossman, Mukesh Harisinghani, Irving J Bigio, Donna Griebel, Donald E Henson, Carol J Fabian, Katherine Ferrara, Sergio Fantini, Mitchell D Schnall, Jo Anne Zujewski, Wendy Hayes, Eric A Klein, Angelo DeMarzo, Iclal Ocak, Jeffrey A Ketterling, Clare Tempany, Faina Shtern, Howard L Parnes, Jorge Gomez, Sudhir Srivastava, Eva Szabo, Stephen Lam, Eric J Seibel, Pierre Massion, Geoffrey McLennan, Kevin Cleary, Robert Suh, Randall W Burt, Ruth M Pfeiffer, John M Hoffman, Hemant K Roy, Thomas Wang, Paul J Limburg, Wafik S El-Deiry, Vali Papadimitrakopoulou, Walter N Hittelman, Calum MacAulay, Robert W Veltri, Diane Solomon, Jose Jeronimo, Rebecca Richards-Kortum, Karen A Johnson, Jaye L Viner, Steven P Stratton, Milind Rajadhyaksha, Atam Dhawan.
Abstract
The concept of intraepithelial neoplasm (IEN) as a near-obligate precursor of cancers has generated opportunities to examine drug or device intervention strategies that may reverse or retard the sometimes lengthy process of carcinogenesis. Chemopreventive agents with high therapeutic indices, well-monitored for efficacy and safety, are greatly needed, as is development of less invasive or minimally disruptive visualization and assessment methods to safely screen nominally healthy but at-risk patients, often for extended periods of time and at repeated intervals. Imaging devices, alone or in combination with anticancer drugs, may also provide novel interventions to treat or prevent precancer.Entities:
Mesh：
Year: 2007 PMID： 17655039 DOI： 10.3233/cbm-2007-3101
Source DB: PubMed Journal: Cancer Biomark ISSN： 1574-0153 Impact factor: 4.388